These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Inhibition of selective adhesion molecules in treatment of inflammatory bowel disease. Ghosh N; Chaki R; Mandal SC Int Rev Immunol; 2012 Oct; 31(5):410-27. PubMed ID: 23083349 [TBL] [Abstract][Full Text] [Related]
7. Physiological basis for novel drug therapies used to treat the inflammatory bowel diseases. I. Immunology and therapeutic potential of antiadhesion molecule therapy in inflammatory bowel disease. Van Assche G; Rutgeerts P Am J Physiol Gastrointest Liver Physiol; 2005 Feb; 288(2):G169-74. PubMed ID: 15647604 [TBL] [Abstract][Full Text] [Related]
9. Leukocyte Anti-Trafficking Strategies: Current Status and Future Directions. Sands BE Dig Dis; 2017; 35(1-2):13-20. PubMed ID: 28147349 [TBL] [Abstract][Full Text] [Related]
10. Development of drugs to target interactions between leukocytes and endothelial cells and treatment algorithms for inflammatory bowel diseases. Danese S; Panés J Gastroenterology; 2014 Nov; 147(5):981-9. PubMed ID: 25220794 [TBL] [Abstract][Full Text] [Related]
11. Alpha4-integrin antagonism--an effective approach for the treatment of inflammatory diseases? Davenport RJ; Munday JR Drug Discov Today; 2007 Jul; 12(13-14):569-76. PubMed ID: 17631252 [TBL] [Abstract][Full Text] [Related]
12. Leukocyte traffic control: a novel therapeutic strategy for inflammatory bowel disease--an update. Cesarini M; Fiorino G Expert Rev Clin Immunol; 2013 Apr; 9(4):301-6. PubMed ID: 23557266 [TBL] [Abstract][Full Text] [Related]
13. Anti-Integrins for the Treatment of Inflammatory Bowel Disease: Current Evidence and Perspectives. Gubatan J; Keyashian K; Rubin SJS; Wang J; Buckman CA; Sinha S Clin Exp Gastroenterol; 2021; 14():333-342. PubMed ID: 34466013 [TBL] [Abstract][Full Text] [Related]
14. Lymphocyte homing antagonists in the treatment of inflammatory bowel diseases. Saruta M; Papadakis KA Gastroenterol Clin North Am; 2014 Sep; 43(3):581-601. PubMed ID: 25110260 [TBL] [Abstract][Full Text] [Related]
15. The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases. Soler D; Chapman T; Yang LL; Wyant T; Egan R; Fedyk ER J Pharmacol Exp Ther; 2009 Sep; 330(3):864-75. PubMed ID: 19509315 [TBL] [Abstract][Full Text] [Related]
16. Modifying T-cell trafficking to the intestinal as a potential management for inflammatory bowel disease. Lawrance IC Expert Opin Investig Drugs; 2012 Jul; 21(7):975-84. PubMed ID: 22612537 [TBL] [Abstract][Full Text] [Related]